EMPA-REG OUTCOME: The Endocrinologist's Point of View

American Journal of Medicine

Volumn 130, Issue 6, 2017, Pages S51-S56

  Perreault, Leigh ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Cardiovascular outcomes; EMPA REG OUTCOME; Empagliflozin; Major adverse cardiovascular events; Type 2 diabetes mellitus

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; SODIUM GLUCOSE COTRANSPORTER 2; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN;

ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL OUTCOME; CLINICAL PRACTICE; ENDOCRINOLOGIST; GLUCOSE BLOOD LEVEL; HEALTH CARE QUALITY; HEART FAILURE; HOSPITALIZATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; METABOLISM; PATHOPHYSIOLOGY;

BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85020115713     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2017.04.005     Document Type: Article

References (44)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
2. Duckworth, W., Abraira, C., Moritz, T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009), 129–139.
3. Gerstein, H.C., Miller, M.E., Byington, R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
4. Patel, A., MacMahon, S., Chalmers, J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
5. Nissen, S.E., Wolski, K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007), 2457–2471.
6. Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf Accessed November 28, 2016.
7. Green, J.B., Bethel, M.A., Armstrong, P.W., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
8. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
9. Pfeffer, M.A., Claggett, B., Diaz, R., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
10. Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
11. White, W.B., Cannon, C.P., Heller, S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
12. Zannad, F., Cannon, C.P., Cushman, W.C., et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385 (2015), 2067–2076.
13. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
14. Thrasher, J., Management of type 2 diabetes mellitus: available therapies. Am J Cardiol 130 (2017), S4–S17.
15. Wanner, C., EMPA-REG OUTCOME: the nephrologist's point of view. Am J Cardiol 130 (2017), S63–S72.
16. Staels, B., Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: potential mechanisms of action. Am J Cardiol 130 (2017), S30–S39.
17. Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
18. Gaede, P., Oellgaard, J., Carstensen, B., et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 59 (2016), 2298–2307.
19. Abdul-Ghani, M., Del Prato, S., Chilton, R., DeFronzo, R.A., SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care 39 (2016), 717–725.
20. Trujillo, J.M., Wettergreen, S.A., Nuffer, W.A., Ellis, S.L., McDermott, M.T., Cardiovascular outcomes of new medications for type 2 diabetes. Diabetes Technol Ther 18 (2016), 749–758.
21. Colhoun, H.M., Betteridge, D.J., Durrington, P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004), 685–696.
22. Kearney, P.M., Blackwell, L., Collins, R., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371 (2008), 117–125.
23. Gaede, P., Valentine, W.J., Palmer, A.J., et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care 31 (2008), 1510–1515.
24. Goldstein, S., Fagerberg, B., Hjalmarson, A., et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiol 38 (2001), 932–938.
25. Packer, M., Fowler, M.B., Roecker, E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106 (2002), 2194–2199.
26. Zannad, F., Gattis Stough, W., Rossignol, P., et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 33 (2012), 2782–2795.
27. ® trial. Eur Heart J 37 (2016), 1526–1534.
28. Raz, I., Cahn, A., Heart failure: SGLT2 inhibitors and heart failure – clinical implications. Nat Rev Cardiol 13 (2016), 185–186.
29. Pham, S.V., Chilton, R., EMPA-REG OUTCOME: the cardiologist's point of view. Am J Cardiol 130 (2017), S57–S62.
30. DeFronzo, R.A., The EMPA-REG study: what has it told us? A diabetologist's perspective. J Diabetes Complications 30 (2016), 1–2.
31. Ferrannini, E., Mark, M., Mayoux, E., CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39 (2016), 1108–1114.
32. Mudaliar, S., Alloju, S., Henry, R.R., Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 39 (2016), 1115–1122.
33. Ferrannini, E., Muscelli, E., Frascerra, S., et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124 (2014), 499–508.
34. Ferrannini, E., Baldi, S., Frascerra, S., et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65 (2016), 1190–1195.
35. Cotter, D.G., Schugar, R.C., Crawford, P.A., Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol 304 (2013), H1060–H1076.
36. Dedkova, E.N., Blatter, L.A., Role of beta-hydroxybutyrate, its polymer poly-beta-hydroxybutyrate and inorganic polyphosphate in mammalian health and disease. Front Physiol, 5, 2014, 260.
37. American Diabetes Association. Standards of Medical Care in Diabetes-2017. Diabetes Care 40 (2017), S4–S5.
38. Arnold, S.V., Inzucchi, S.E., Maddox, T.M., et al. Defining the potential “real-world” impact of the EMPA-REG OUTCOME trial on improving cardiovascular outcomes: observations from the Diabetes Collaborative Registry (DCR). Diabetologia, 59(Suppl 1), 2016 Abstract #729.
39. ® (empagliflozin) tablets, for oral use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204629s008lbl.pdf Accessed December 19, 2016.
40. Neal, B., Perkovic, V., de Zeeuw, D., et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)–a randomized placebo-controlled trial. Am Heart J 166 (2013), 217–223e11.
41. Food and Drug Administration. FDA drug safety communication: interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet); FDA to investigate. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm500965.htm Accessed June 1, 2016.
42. Bilezikian, J.P., Watts, N.B., Usiskin, K., et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab 101 (2016), 44–51.
43. ® (canagliflozin) tablets, for oral use. Available at: https://www.invokanahcp.com/sites/www.invokanahcp.com/files/prescribing-information-invokana.pdf Accessed April 11, 2017.
44. ® (dapagliflozin) tablets, for oral use. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202293s011lbl.pdf Accessed April 11, 2017.